Lancashire and South Cumbria
Formulary
Formulary
9 Nutrition and blood
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
09-01-06 Drugs used in neutropenia
| Filgrastim |
|
Formulary
|
| Injection 12 million units in 0.2mL prefilled syringe, 30 million units & 48 million units in 0.5mL prefilled syringe |
 MHRA: Filgrastim and pegfilgrastim: risk of capillary leak syndrome |
|
| Pegfilgrastim Neulasta® |
|
Formulary
|
| Injection 6mg in 0.6mL prefilled syringe |
|
MHRA: Filgrastim and pegfilgrastim: risk of capillary leak syndrome |
|
|
Links
- MHRA Drug Safety Update Sept 2013: Filgrastim and pegfilgrastim: risk of capillary leak syndrome
- MHRA Drug Safety Update September 2013: Filgrastim and pegfilgrastim: risk of capillary leak syndrome
- MHRA: Filgrastim and pegfilgrastim: risk of capillary leak syndrome
- MHRA: Filgrastim and pegfilgrastim: risk of capillary leak syndrome
- NICE NG203: Chronic kidney disease: assessment and management
- NICE TA743: Crizanlizumab for preventing sickle cell crises in sickle cell disease